A Medical Device Daily

VolitionRX (Singapore), a life sciences company focused on developing blood-based diagnostic tests, said it has filed a patent application building on its Nucleosomics technology platform.

VolitionRX has developed methods to detect nucleosome adducts of cancer origin which are circulating in the blood of cancer patients and has filed a patent application covering both the use of these adducts as biomarkers and the methods for their detection. The new patent application, “Method For Detecting Nucleosome Adducts“ was filed on Dec. 7. The existence of these nucleosome adducts was previously unknown, the company noted.

“We have high hopes that these advances will find application in the diagnosis of certain cancers, particularly cancers whose growth is steroid dependent,“ said Jake Micallef, chief scientific officer of Belgian Volition.

VolitionRX's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.